Advertisement
Treatment outcomes and paving the way for an HIV cure in Low and Middle Income Countries
Edited by Dr Eric Arts, Dr Nicaise Ndembi and Dr Denis Tebit
Discussion of HIV treatment outcomes in LMICs has historically been neglected, even though it is in these countries that a cure is most crucial. This series covers the ways treatment outcomes can be improved along the way to a HIV cure in states defined as LMICs by the WHO.
Currently open for submissions - submit to the series here
Eric J Arts is Chair of the Department of Microbiology and Immunology at Western University in London, Canada. His research for the past 16 years described in over 120 publications has focused on HIV-1 fitness, evolution, and virulence in regards to transmission, disease progression, immune escape, drug resistance, and global HIV spread.
Since 1998, he has directed the research laboratories at the Joint Clinical Research Centre, Kampala, Uganda and has collaborated with investigators in Zimbabwe, China, Cameroon, Belgium, UK, France, Brazil, and Argentina. His research has been supported by grants from the NIH (NIAID, NICHD, and NHLBI), from the State of Ohio, Merck, and amfAR. He has served as chair and member of the NIH and CIHR grant panel and has reviewed grants for the many governments around the world.
Dr Mark Boyd is Professor and Chair of Medicine at the University of Adelaide based at the Lyell McEwin Hospital. He is the current President of the Australasian Society for HIV, Viral Hepatitis and Sexual Health Medicine (ASHM).
Dr Boyd has published the SECOND-LINE and Encore1 studies, the results of which have been incorporated into the most recent (2016) WHO integrated guidelines for the management of HIV-infection.
In 2014, Dr Boyd was awarded the prestigious Frank Fenner Prize for Advanced Research in Infectious Diseases by the Australasian Society for Infectious Diseases (ASID). Dr Boyd has attracted over 20 million AUD in research funding from government, industry and non-government organisational sources. He collaborates with colleagues in HIV clinical research worldwide, particularly in the Asia-Pacific region.
Advertisement
Speed
80 days to first decision for reviewed manuscripts only
35 days to first decision for all manuscripts
118 days from submission to acceptance
13 days from acceptance to publication
Citation Impact
2.240 - 2-year Impact Factor
2.296 - 5-year Impact Factor
0.913 - Source Normalized Impact per Paper (SNIP)
1.143 - SCImago Journal Rank (SJR)
Usage
204,811 Downloads
156 Altmetric Mentions
Advertisement
